Advertisement
UK markets close in 3 hours 16 minutes

  • FTSE 100

    8,231.10
    +25.99 (+0.32%)
     

  • FTSE 250

    20,446.69
    +65.64 (+0.32%)
     

  • AIM

    774.12
    -3.38 (-0.43%)
     

  • GBP/EUR

    1.1833
    -0.0001 (-0.01%)
     

  • GBP/USD

    1.2684
    -0.0038 (-0.30%)
     

  • Bitcoin GBP

    52,248.18
    +821.85 (+1.60%)
     

  • CMC Crypto 200

    1,374.89
    -7.78 (-0.56%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CRUDE OIL

    81.73
    +0.16 (+0.20%)
     

  • GOLD FUTURES

    2,353.50
    +6.60 (+0.28%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     

  • DAX

    18,157.94
    +90.03 (+0.50%)
     

  • CAC 40

    7,638.70
    +68.50 (+0.90%)
     
Money:

Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

BridgeBio Pharma, Inc.
·1-min read
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.

PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc. 
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Contact: 
Vikram Bali 
contact@bridgebio.com 
(650)-789-8220